Albuminuria as a marker of arterial stiffness in chronic kidney disease patients

Table 1 Demographic and aortic stiffness indices characteristics

Patients characteristics	Study population	Patients with moderately increased albuminuria	Patients with severely increased albuminuria	P value
No	115	58	57	-
Age (yr)	52.6 ± 14.6	51.4 ± 14.4	54.2 ± 15.07	NS
Sex (M/F), (n)	76/39	39/19	37/20	NS
BMI (kg/m2)	30.9 ± 19.3	28.6 ± 4.5	33.9 ± 28.2	< 0.03
Smoking, n (%)	5	3	2	NS
pSBP (mmHg)	138.0 ± 14.2	139 ± 12.7	138.0 ± 15.5	NS
pDBP (mmHg)	84.2 ± 9.7	84.9 ± 10.7	82.6 ± 9.8	NS
pPP (mmHg)	57.9 ± 15.9	56.7 ± 15.1	59.4 ± 16.9	NS
cSBP (mmHg)	130.3 ± 14.6	130 ± 13.3	130.2 ± 16.5	NS
cDBP(mmH)	84.2 ± 9.7	84.9 ± 10.7	84.3 ± 8.6	NS
cPP (mmHg)	48.1 ± 17.6	47.9 ± 17.9	48.4 ± 17.8	NS
AIx (%)	21.1 ± 10.6	18.4 ± 10.0	24.5 ± 10.0	< 0.004
PWVc-f (m/sec)	8.7 ± 2.0	8.3 ± 2.0	9.1 ± 1.9	< 0.02
ACEIs, n (%)
(ramipril or quinapril)	100 (86)	56 (96)	44 (77)	NS
AT1 RB, n (%)
(valsartan or olmesartan)	20 (17.4)	9 (15.5)	11 (19.2)	NS
CCBs, n (%)	11 (9.5)	6 (10.3)	5 (8.7)	NS
Statins, n (%)	7 (6.08)	3 (5.1)	4 (7.01)	NS

Data are presented as mean value. M/F: Male/female; BMI: Body mass index; pSBP: Peripheral systolic blood pressure; pDBP: Peripheral Diastolic blood pressure; pPP: Peripheral pulse pressure; cSBP: Central systolic blood pressure; cDBP: Central diastolic blood pressure; cPP: Central pulse pressure; AIx: Augmentation index; AP: Augmentation pressure; PWVc-f: Pulse wave velocity carotid-femoral; ACEIs: Angiotensin converting enzyme inhibitors; AT1RB: Angiotensin type 1 receptor blockers; CCBs: Calcium channel blockers.